GSK and Isis will co-develop drugs for rare diseases

03/31/2010 | Google

GlaxoSmithKline could pay Isis Pharmaceuticals as much as $1.5 billion in a deal involving the use of Isis' antisense technology to develop as many as six treatments for rare diseases. The technology works by blocking messenger RNA to inhibit the production of disease-causing proteins.

View Full Article in: